On June 9, the FDA approved Enflonsia, the first preventive antibody shot aimed at safeguarding infants up to one year old from Respiratory Syncytial Virus (RSV). This viral infection is the leading cause of hospitalization in infants, presenting symptoms that can mimic the common cold but may escalate to serious conditions like apnea and pneumonia. Drug manufacturer Merck is committed to ensuring the availability of Enflonsia ahead of the upcoming RSV season. While there are vaccines for adults, this represents a significant advancement for infant care, offering passive immunity where previous options were limited.
Enflonsia is the first preventive antibody shot approved for infants up to 1 year to protect against RSV, a leading cause of hospitalization.
Unlike vaccines, which stimulate the immune system for active immunity, Enflonsia offers passive immunity through administered antibodies, crucial for infant protection.
Merck is dedicated to making Enflonsia available before the RSV season, emphasizing the need for preventative measures for vulnerable infants.
Mild RSV in infants can seem like a common cold, but severe cases can lead to apnea, wheezing, and pneumonia, highlighting the importance of prevention.
Collection
[
|
...
]